Positive results from Phase III OPTIMIZE-1 trial of once daily OCS-01

Swiss ophthalmology specialist Oculis Holding (Nasdaq: OCS) has announced that Dr Eric Donnenfeld, presented the positive results from the Phase III OPTIMIZE-1 trial of OCS-01 for the treatment of inflammation and pain following cataract surgery at the 2024 American Society of Cataract and Refractive Surgery (ASCRS Annual Meeting, which took place April 5-8, 2024, in Boston, MA.

The results showed that 57.2% of patients treated with OCS-01 were inflammation free (i.e. absence of anterior chamber cells) at Day 15 (versus 24.0% with vehicle, p<0.0001), and 75.5% had absence of ocular pain at Day 4 (vs 52.0% with vehicle, p<0.0001).

Leveraging Oculis’ proprietary OPTIREACH technology, OCS-01 is a novel, high concentration dexamethasone eye drop. The OPTIREACH solubilizing formulation technology addresses the main limitations of conventional eye drops by improving the solubility of lipophilic drugs, increasing the residence time on the eye surface and thereby, enabling less frequent administration for front-of-the-eye and the drug passage from the eye surface to the posterior segment for back-of-the-eye diseases.